Amanda Yopp Discusses the Challenges With Treating Multiple Myeloma Patients

Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.